Innovent Biologics, Inc. (HKG:1801)
Hong Kong
· Delayed Price · Currency is HKD 84.90
+2.30 (2.78%)
Apr 29, 2026, 4:08 PM HKT
Innovent Biologics Cash Flow Statement
Financials in millions CNY. Fiscal year is January - December.
Millions CNY. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | - | -94.63 | -1,028 | -2,179 | -2,729 | Upgrade
|
| Depreciation & Amortization | - | 332.16 | 310.22 | 276.79 | 202.17 | Upgrade
|
| Other Amortization | - | 87.61 | 74.89 | 42.64 | 2.58 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 22.99 | 0.95 | -0.06 | 0.71 | Upgrade
|
| Asset Writedown & Restructuring Costs | - | 632.57 | 115.36 | - | - | Upgrade
|
| Loss (Gain) From Sale of Investments | - | -179.03 | -30.81 | -5.1 | -125.02 | Upgrade
|
| Loss (Gain) on Equity Investments | - | 41.01 | - | - | - | Upgrade
|
| Stock-Based Compensation | - | 556.52 | 574.2 | 469.49 | 501.57 | Upgrade
|
| Other Operating Activities | - | -515.93 | -272.47 | -833.19 | 213.88 | Upgrade
|
| Change in Accounts Receivable | - | -178.52 | -430.62 | 393.14 | -493.03 | Upgrade
|
| Change in Inventory | - | 180.63 | 358.95 | -105.39 | -643.28 | Upgrade
|
| Change in Accounts Payable | - | -14.87 | 46.93 | 130.57 | 74.43 | Upgrade
|
| Change in Unearned Revenue | - | -31.19 | -138.63 | 205.04 | 105.43 | Upgrade
|
| Change in Other Net Operating Assets | - | 447.71 | 566.77 | -313.45 | 864.46 | Upgrade
|
| Operating Cash Flow | - | 1,287 | 147.81 | -1,919 | -2,025 | Upgrade
|
| Operating Cash Flow Growth | - | 770.73% | - | - | - | Upgrade
|
| Capital Expenditures | - | -965.67 | -1,119 | -896.9 | -1,066 | Upgrade
|
| Sale of Property, Plant & Equipment | - | 0.27 | 0.05 | 0.19 | 0.1 | Upgrade
|
| Sale (Purchase) of Intangibles | - | -676.42 | -262.35 | -468.6 | -781.88 | Upgrade
|
| Sale (Purchase) of Real Estate | - | - | 16.23 | - | - | Upgrade
|
| Investment in Securities | - | -981.19 | -204.43 | -384.74 | -254.58 | Upgrade
|
| Other Investing Activities | - | 1,458 | 571.22 | 314.87 | -596.15 | Upgrade
|
| Investing Cash Flow | - | -1,165 | -998.66 | -1,435 | -2,698 | Upgrade
|
| Long-Term Debt Issued | - | 515.57 | 1,336 | 1,080 | 1,463 | Upgrade
|
| Long-Term Debt Repaid | - | -1,246 | -948.85 | -392.74 | -278.72 | Upgrade
|
| Net Debt Issued (Repaid) | - | -730.44 | 386.7 | 687.43 | 1,184 | Upgrade
|
| Issuance of Common Stock | - | 84.31 | 2,255 | 2,131 | 3,951 | Upgrade
|
| Other Financing Activities | - | 39.5 | -54.56 | 73.59 | -131.52 | Upgrade
|
| Financing Cash Flow | - | -606.63 | 2,587 | 2,892 | 5,003 | Upgrade
|
| Foreign Exchange Rate Adjustments | - | 12.68 | -6.88 | 118.66 | -197.14 | Upgrade
|
| Net Cash Flow | - | -472.34 | 1,730 | -343.24 | 83.23 | Upgrade
|
| Free Cash Flow | - | 321.36 | -971.58 | -2,816 | -3,090 | Upgrade
|
| Free Cash Flow Margin | - | 3.41% | -15.65% | -61.80% | -72.38% | Upgrade
|
| Free Cash Flow Per Share | - | 0.20 | -0.62 | -1.89 | -2.12 | Upgrade
|
| Cash Interest Paid | - | 122.43 | 127.61 | 104.88 | 78.83 | Upgrade
|
| Cash Income Tax Paid | - | 0.16 | -114.42 | 66.1 | 26.44 | Upgrade
|
| Levered Free Cash Flow | - | -113.22 | -907.54 | -2,475 | -2,612 | Upgrade
|
| Unlevered Free Cash Flow | - | -70.94 | -845.9 | -2,411 | -2,573 | Upgrade
|
| Change in Working Capital | - | 403.76 | 403.39 | 309.91 | -91.98 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.